CD22 and acute lymphoblastic leukemia: In this case series, we report that repeated treatments with locally manufactured allogeneic bispecific humanized CD19/CD22-targeting CAR T cells were feasible and associated with durable remission in 2 patients with relapsed/refractory ALL receiving alloHCT and antibody treatments.